TLDR: LONDON—Perceptic, founded by Palantir Life Sciences alumni, emerged from stealth with $12 million seed funding led by Accel to connect AI drug discovery and clinical trial design. The platform is already used by CSL, aiming to reduce handoff losses and speed due diligence and trial data work.
Key Takeaways:
- Three former Palantir executives build Perceptic after years helping life sciences teams deploy commercial AI, targeting pharma R and D systems rather than single models.
- Perceptic says its infrastructure model agnostic platform ties discovery, indication selection, and trial data foundations, including a claimed 50 fold increase in clinical data extractions.
- Accel partner Sonali De Rycker backs the idea of following a drug through its full life cycle, pushing enterprise AI toward a shared workflow and data source of truth.
Pharma has spent years buying point solutions and still running decisions through noisy handoffs. Perceptic is betting the cure for AI hype is plumbing, provenance, and a system that keeps working after the first model output.
Pharma has spent years buying point solutions and still running decisions through noisy handoffs. Perceptic is betting the cure for AI hype is plumbing, provenance, and a system that keeps working after the first model output.
Q&A
If Perceptic promises traceable claims instead of hallucination tolerant shortcuts, what will customers measure first during adoption?
They will likely track auditability metrics like claim source coverage, decision trace depth, and how often AI suggestions can be reproduced from original public, internal, and vendor data.
What is harder for Perceptic than building models: integrating with pharma workflows that already run on legacy databases and approvals?
The tougher part is aligning governance, data provenance requirements, and handoff approvals so teams can trust outputs across discovery to clinical trial design without creating a parallel bureaucratic layer.
Why has AI drug discovery struggled to reach approved products, and how does Perceptic attempt to close that gap?
Many efforts improve one step while upstream and downstream assumptions break at handoffs. Perceptic targets linkage between evidence, indication choices, and trial design to reduce lost context.
What happens next in the fundraising cycle if Perceptic stays focused on three specific R and D areas instead of expanding everywhere?
If it proves measurable cycle time reductions and better trial selection outcomes, follow on investors may fund deeper integrations and broader site deployments rather than chasing an all in platform promise.
Does Perceptic face competition from platform vendors inside big pharma, and how could that reshape its deployment strategy?
Yes, internal and external enterprise AI platforms could reduce Perceptic to a component. That would push Perceptic to strengthen connector depth, compliance tooling, and workflow adoption so it becomes the glue that teams refuse to replace.
Top in Startups
ClickHouse triples revenue as IPO rumors get louder
Bose sleep veteran SOND funds $7M and launches Dreambuds
Cognition books $1B raise as Devin wins enterprise demand
Drew Houston hands Dropbox CEO reins to Ashraf Alkarmi
No comments yet. Be the first to share your thoughts!